查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1820175

数位治疗市场报告，按应用（糖尿病、肥胖症、心血管疾病、中枢神经系统疾病、呼吸系统疾病、戒烟等）、最终用途（患者、提供者、付款人、雇主等）和地区划分，2025 年至 2033 年

Digital Therapeutics Market Report by Application (Diabetes, Obesity, CVD, CNS Disease, Respiratory Diseases, Smoking Cessation, and Others), End Use (Patients, Providers, Payers, Employers, and Others), and Region 2025-2033
出版日期: | 出版商: IMARC | 英文 146 Pages | 商品交期: 2-3个工作天内

价格

2024年，全球数位治疗市场规模达71亿美元。展望未来， IMARC Group预计到2033年，该市场规模将达到287亿美元，2025-2033年期间的复合年增长率（CAGR）为16.8%。北美是该市场的主导地区，因为该地区拥有完善的医疗基础设施、强大的技术进步以及对数位医疗的大量投资。此外，由于医疗支出不断增长、慢性病患病率上升、老年人口不断增长以及技术进步提供了便捷、经济高效的个人化医疗服务，该市场也在不断扩张。

数位治疗市场趋势：

医疗保健技术发展

由于技术的不断进步，特别是在行动应用程式、人工智慧 (AI) 和机器学习 (ML) 方面的进步，数位治疗市场正在快速成长。这些进步促进了先进数位平台的创建，这些平台能够提供客製化的治疗计划、处理大量健康资料并即时追踪患者活动。基于人工智慧的演算法正在增强诊断能力，从而能够早期诊断疾病并进行更有针对性的干预。此外，穿戴式科技的发展补充了血压、心率和血糖水平等不同的生理指标，有助于患者和医护人员积极主动地进行疾病管理。将这些技术整合到医疗保健系统中可以改善患者的治疗效果，并消除面对面咨询的必要性，使治疗更加方便和有效。 IMARCIMARC Group预测，到 2033 年，全球医疗保健人工智慧市场规模预计将达到 687 亿美元。

慢性病发生率上升

慢性病发生率的上升是市场的主要驱动力之一。糖尿病、肥胖症、心血管疾病和呼吸系统疾病等慢性疾病在全球日益普遍，这主要是由于人口老化、缺乏体能活动和不健康饮食等原因造成的。数位疗法透过提供即时监测和客製化干预措施，为长期病情管理提供了解决方案。例如，糖尿病患者可以使用数位平台监测血糖水平，调整胰岛素剂量，并根据即时回馈获得饮食建议。同样，心臟病患者可以利用数位疗法追踪生命体征，接收超出范围的结果通知，并遵循规定的治疗方案。这些技术使患者能够更好地控制病情，最大限度地减少反覆去医院的需要，并提高他们的整体生活品质。 2024 年，处方医疗解决方案 Digital Therapeutics(TM) 领域的领导者 Click Therapeutics, Inc. 透露，有意透过收购 Better Therapeutics, Inc. 的资产，加速其在肥胖症和心臟代谢疾病方面的发展力度。收购的资产包括 AspyreRx (BT-001)，这是 FDA 批准的首个用于治疗 2 型糖尿病的处方数位干预产品，以及 BT-004，该产品最近获得 FDA 突破性设备称号，用于治疗代谢功能障碍相关脂肪性肝炎 (MASH)。

个人化医疗需求增加

根据数位治疗市场报告，个人化医疗正成为医学领域的焦点。患者越来越期望获得根据自身需求量身定制的治疗方案，包括考虑基因、生活方式和特定健康状况等因素。数位治疗使临床医生能够利用即时资讯客製化治疗方案，从而提供更个人化的治疗。这些平台可以利用穿戴式装置、健康史和患者自我报告的资料，制定高度个人化的治疗方案。例如，心理应用程式利用患者情绪、睡眠和行为讯息来调整治疗方法，例如认知行为疗法 (CBT)。同样，慢性病数位疗法能够追踪病情进展，并根据这些资讯调整治疗方案。个人化医疗正在彻底改变医疗保健，使患者能够主动管理自身病情，从而提高治疗效果和参与度。随着个人化治疗需求的日益增长，数位治疗正成为个人化治疗不可或缺的一部分。 2024年，Merz Therapeutics推出iFlexo，这是一款客製化的数位解决方案，旨在改善中风后痉挛患者的康復，体现了其持续致力于帮助中风倖存者的奉献精神。该应用程式与S3 Connected Health合作开发，提供针对性的运动和復健计划，旨在增强轻度至中度痉挛患者的活动能力。透过提供结构化的锻炼，iFlexo致力于帮助中风倖存者恢復独立生活，并提高他们的整体生活品质。 Merz Therapeutics是唯一一家专注于神经毒素研究并提供自我康復支持平台的製药公司。

数位治疗市场成长动力：

监管支援和医疗报销

数位治疗产业发展的关键驱动因素之一是这些平台日益增长的监管支持和报销机制的建立。美国食品药物管理局 (FDA) 等监管机构正在积极验证数位治疗是否为适当的医疗干预措施。 FDA 制定了新的软体治疗审批指南，简化了数位治疗公司将产品推向市场的流程。这项监管批准确保了数位治疗的安全有效，从而获得了更多医疗服务提供者和患者的认可。此外，报销政策也在不断发展以适应数位治疗，越来越多的保险公司认识到这些解决方案在改善患者治疗效果和降低医疗成本方面的价值。随着数位治疗报销范围的扩大，这些解决方案的经济可近性也在提高，使更多患者能够从中受益。监管和报销方面的进展为数位治疗在主流医疗保健中的更广泛应用铺平了道路。

更加重视心理健康

人们对精神健康障碍的认识日益加深，这推动了市场的成长。焦虑、忧郁和创伤后压力症候群 (PTSD) 等精神健康障碍的发生率不断上升，对有效且价格合理的治疗方案的需求也日益增长。数位疗法透过提供可扩展、易于实施且可在家中完成的解决方案，为精神健康障碍的治疗开闢了新的可能性。行动应用程式、线上治疗网站和电脑化认知行为疗法 (CBT) 计画正变得越来越受欢迎，因为它们为患者提供了标准门诊治疗之外的选择。这些选择对于居住在农村或欠发达地区、难以获得心理健康专业人士帮助的人尤其有用。此外，线上心理健康网站提供了一定程度的匿名性，可以减少寻求帮助的耻辱感。

消费者对便利性和远距医疗的偏好

对便捷远距医疗产品和服务的偏好正在推动市场成长。如今，患者越来越希望获得能够融入其积极生活方式的医疗保健解决方案，以便他们能够自行照顾自身健康，而无需反覆前往诊所或医院。数位疗法透过提供随时随地可用的工具来满足这项需求，帮助患者以自己的步调掌控健康。例如，慢性病患者可以使用行动应用程式和穿戴式技术来监测自身症状、生命征象并获得治疗建议。此外，数位平台也方便与医疗专业人员进行远距会诊，从而减少出行需求并降低医疗费用。

数位治疗市场细分：

按应用分类：

  • 糖尿病
  • 肥胖
  • 化学气相沉积
  • 中枢神经系统疾病
  • 呼吸系统疾病
  • 戒烟
  • 其他的

糖尿病占据了大部分市场份额

糖尿病占据最大的市场份额，因为它影响着全球数百万人。此外，该领域的数位疗法利用尖端技术监测血糖水平、管理胰岛素剂量并提供个人化的饮食和运动建议。这些工具旨在透过使疾病管理更易于访问和高效来稳定患者病情并提高生活品质。因此，领先的市场参与者正在推出先进的产品来满足这些需求。例如，2023 年 10 月 16 日，心臟代谢疾病处方数位疗法 (PDT) 领域的杰出领导者 Better Therapeutics, Inc. 宣布商业发布 AspyreRx。这是第一个获得美国食品药物管理局 (FDA) 批准作为管理成人 2 型糖尿病 (T2D) 的 II 类设备的认知行为疗法 (CBT) 应用程式。它允许医疗保健提供者开立 AspyreRx 处方，该应用程式可从 Apple App Store 和 Google Play Store 下载。

依最终用途分类：

  • 患者
  • 提供者
  • 付款人
  • 雇主
  • 其他的

患者占业界最大份额

根据数位治疗行业概览，由于以患者为中心的医疗保健模式日益普及，以及智慧型手机和互联网服务的广泛应用，患者成为最大的细分市场，这使得获取治疗应用更加便捷。这些数位解决方案为患者提供各种疾病的客製化治疗方案，包括糖尿病、高血压等慢性疾病以及精神健康障碍。此外，这些应用程式透过个人化护理计划和即时健康追踪来管理健康状况的便利性和有效性，极大地促进了患者对其的采用。医疗保健数位化的不断发展以及向预防性医疗保健措施的转变进一步推动了这一趋势，巩固了患者在数位治疗市场的主导地位。因此，主要参与者正在合作并推出先进的产品。例如，2023年7月5日，瑞思迈宣布收购领先的睡眠和呼吸照护数位诊断软体供应商Somnoware。此次收购扩展了瑞思迈的睡眠管理软体功能，透过增强的睡眠实验室和医生工具，促进更有效率的患者诊断和长期治疗。 Somnoware 平台将补充瑞思迈现有的 AirView 和 Brightree 后侦测解决方案，并将继续以开放平台的形式运作。这种开放性使睡眠实验室、肺功能检测机构和医生能够存取各种检测解决方案的结果，从而加快确诊患者获得所需治疗的进程。

按地区划分：

  • 北美洲
    • 美国
    • 加拿大
  • 亚太
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲

北美引领市场，占据最大的数位治疗市场份额

该报告还对所有主要区域市场进行了全面分析，包括北美（美国和加拿大）；欧洲（德国、法国、英国、义大利、西班牙、俄罗斯等）；亚太地区（中国、日本、印度、韩国、澳洲、印尼等）；拉丁美洲（巴西、墨西哥等）；以及中东和非洲。报告指出，北美是数位疗法最大的区域市场。

北美是该市场的领先地区。该地区数位治疗市场的成长因素包括完善的医疗基础设施、强劲的技术进步以及对数位健康的大量投资。此外，美国数位治疗市场的成长主要得益于医疗服务提供者和患者对数位健康技术的广泛采用。此外，北美主要数位治疗公司的存在，加上有利的政府政策和人们对数位治疗益处日益增长的认识，进一步推动了市场的成长。例如，2023年11月7日，虚拟心臟代谢护理领域的领导者Vida Health与高级日常穿戴装置领域的主要参与者Withings Health Solutions合作，为Vida会员提供顶级数位监测设备。此次合作使符合条件的Vida会员可以使用Withings Body Pro蜂窝体重计、BPM Connect Pro蜂窝血压监测仪或两者兼有。 Vida的护理团队获得了可靠且一致的患者生成的健康资料，从而透过使用这些设备增强了他们的个人化护理策略并改善了健康结果。

（请注意，这只是关键参与者的部分名单，完整名单将在报告中提供。）

  • 目前，各公司正在策略性地增强其产品服务，扩大其覆盖范围，以促进数位疗法市场的成长。此外，他们努力的核心是与成熟的医疗机构和保险公司建立合作伙伴关係，这有助于将数位疗法融入主流医疗实践，并提高患者的可及性。此外，各公司也不断创新，推动其技术进步，透过更个人化和有效的治疗来提高患者的参与度和治疗效果。同时，各公司也积极争取监管部门的批准，以确保合规性并提升市场信誉，这对于数位疗法的广泛应用至关重要。此外，各公司也投资进行教育活动，以提高医疗专业人士和患者对数位疗法益处的认识，旨在转变观念，建立信任。这些共同努力对于推动数位疗法在医疗领域的应用和长期发展至关重要。

本报告回答的关键问题

  • 2024 年全球数位治疗市场规模是多少
  • 2025-2033年全球数位治疗市场的预期成长率是多少
  • 推动全球数位治疗市场的关键因素有哪些
  • COVID-19 对全球数位治疗市场有何影响
  • 根据应用情况，全球数位治疗市场如何划分？
  • 根据最终用途，全球数位治疗市场如何划分
  • 全球数位治疗市场的主要区域有哪些
  • 全球数位治疗市场的主要参与者/公司有哪些

本报告回答的关键问题

  • 2024年全球数位治疗市场规模？ 2025-2033年全球数位治疗市场的预期成长率是多少？
  • 推动全球数位治疗市场发展的关键因素有哪些？
  • COVID-19 对全球数位治疗市场有何影响？
  • 根据应用，全球数位治疗市场如何分布？
  • 根据最终用途，全球数位治疗市场如何划分？
  • 全球数位治疗市场的主要区域有哪些？
  • 全球数位治疗市场的主要参与者/公司有哪些？

目录

第一章：前言

第二章：范围与方法

  • 研究目标
  • 利害关係人
  • 资料来源
    • 主要来源
    • 二手资料
  • 市场评估
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第三章：执行摘要

第四章：简介

第五章：全球数位治疗市场

  • 市场概况
  • 市场表现
  • COVID-19的影响
  • 市场预测

第六章：市场区隔：依应用

  • 糖尿病
  • 肥胖
  • 化学气相沉积
  • 中枢神经系统疾病
  • 呼吸系统疾病
  • 戒烟
  • 其他的

第 7 章：市场区隔：最终用途别

  • 患者
  • 提供者
  • 付款人
  • 雇主
  • 其他的

第八章：市场区隔：依地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲

第九章：SWOT分析

第 10 章：价值链分析

第 11 章：波特五力分析

第 12 章：价格分析

第 13 章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • 2Morrow Inc.
    • Canary Health Inc.
    • Click Therapeutics Inc.
    • Mango Health Inc. (TrialCard Incorporated)
    • Noom Health Inc.
    • Omada Health Inc.
    • Pear Therapeutics, Inc.
    • Propeller Health (ResMed)
    • Teladoc Health Inc.
    • Voluntis Inc.
    • WellDoc Inc.
Product Code: SR112025A3889

The global digital therapeutics market size reached USD 7.1 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 28.7 Billion by 2033, exhibiting a growth rate (CAGR) of 16.8% during 2025-2033. North America is the dominant region in the market because it has an established healthcare infrastructure, strong technology advancements, and high investment in digital health in the region. Moreover, the market is expanding due to rising healthcare expenditure, increasing prevalence of chronic diseases, the growing geriatric population, and technological advancements offering easily accessible, cost-effective, personalized medical treatments.

Digital Therapeutics Market Trends:

Technological Developments in Healthcare

The market for digital therapeutics is growing at a rapid pace because of the relentless progress in technology, especially in mobile applications, artificial intelligence (AI), and machine learning (ML). These advancements are facilitating the creation of advanced digital platforms that are capable of providing customized treatment plans, processing large volumes of health data, and tracking patient activity in real-time. Algorithms based on AI are enhancing diagnostic capabilities, enabling early diagnosis of disease and more targeted interventions. Additionally, the development of wearable technology, which complements different physiological measures, such as blood pressure, heart rate, and blood glucose levels, is facilitating patients and healthcare workers to be proactive in disease management. The integration of these technologies into healthcare systems is enhancing patient outcomes and eliminating the necessity for in-person consultations, making treatment more convenient and effective. IMARC Group predicts that the global artificial intelligence in healthcare market is projected to reach USD 68.7 Billion by 2033.

Rising Incidence of Chronic Diseases

The rising occurrence of chronic diseases is one of the primary drivers of market. Chronic diseases like diabetes, obesity, cardiovascular diseases, and respiratory ailments are becoming prevalent globally, largely because of reasons such as aging populations, a lack of physical activity, and unhealthy diets. Digital therapeutics provide a solution for long-term condition management by offering real-time monitoring and tailored interventions. For instance, diabetic patients can use digital platforms to monitor their blood glucose levels, modify their insulin dosage, and get diet suggestions based on real-time feedback. Likewise, heart disease patients can utilize digital therapeutics to track vital signs, get notifications for out-of-range results, and follow prescribed treatment protocols. These technologies allow for patients to better control their conditions, minimizing the need for repeated trips to the hospital and enhancing their overall quality of life. In 2024, Click Therapeutics, Inc., a frontrunner in Digital Therapeutics(TM) as prescription medical solutions, revealed intentions to expedite its development efforts in obesity and cardiometabolic conditions through purchasing the assets of Better Therapeutics, Inc. The acquired assets comprise AspyreRx (BT-001), the inaugural FDA-authorized prescription digital intervention for type 2 diabetes, and BT-004, which recently received FDA Breakthrough Device Designation for addressing metabolic dysfunction-associated steatohepatitis (MASH).

Increased Demand for Personalized Healthcare

As per digital therapeutics market report, personalized healthcare is emerging as the central focus in medicine. Increasingly, patients expect therapies that are customized to their own requirements, including considerations such as genetics, lifestyle, and particular health status. Digital therapeutics allow clinicians to provide more personalized therapies by employing real-time information to customize treatment plans. The platforms can draw on data from wearable devices, health histories, and self-reported information to generate extremely personalized treatment plans. For instance, psychological apps utilize information regarding a patient's mood, sleep, and behavior to modify therapeutic treatments such as cognitive behavioral therapy (CBT). Likewise, chronic condition digital therapeutics are capable of tracking disease advancement and modifying treatments based on the information. Personalized healthcare is revolutionizing healthcare by enabling patients to actively manage their condition, enhancing both treatment efficacy and participation. With the need for personalized therapies increasing, digital therapeutics are becoming integral parts of personalized treatments. In 2024, Merz Therapeutics introduces iFlexo, a tailored digital solution designed to improve rehabilitation for individuals experiencing post-stroke spasticity, reflecting its continuous dedication to assisting stroke survivors. The application, created in partnership with S3 Connected Health, offers specific exercises and rehabilitation plans designed to enhance mobility for individuals experiencing mild to moderate spasticity. Through providing structured exercises, iFlexo seeks to assist stroke survivors in reclaiming their independence and enhancing their overall life quality. Merz Therapeutics is the sole pharmaceutical company specializing in neurotoxins that provides a platform for self-rehabilitation support.

Digital Therapeutics Market Growth Drivers:

Regulatory Support and Healthcare Reimbursement

One of the key drivers behind the digital therapeutics industry is the growing regulatory support and creation of reimbursement mechanisms for these platforms. Regulators such as the U.S. Food and Drug Administration (FDA) are actively engaging in the verification of digital therapeutics as proper medical interventions. The FDA has established new guidelines for the approval of software-based treatments, which is streamlining the process for digital therapeutics companies to take their products to market. This regulatory approval ensures that digital therapeutics are safe and effective, thus gaining more acceptance from healthcare providers and patients. Moreover, reimbursement policies are evolving to accommodate digital therapeutics, with more insurance companies recognizing the value of these solutions in improving patient outcomes and reducing healthcare costs. As reimbursement for digital therapies becomes more widespread, the financial accessibility of these solutions is improving, allowing more patients to benefit from them. This regulatory and reimbursement progress is paving the way for the broader adoption of digital therapeutics in mainstream healthcare.

Greater Emphasis on Mental Health

The increasing recognition of mental health disorders is supporting the market growth. Mental health disorders like anxiety, depression, and post-traumatic stress disorder (PTSD) are rising in frequency, and there is a growing need for effective, affordable treatments. Digital therapeutics are opening up new possibilities for treating mental health disorders by presenting scalable, easy-to-deliver solutions that can be delivered from home. Mobile apps, online therapy websites, and computerized cognitive behavioral therapy (CBT) programs are becoming increasingly popular as they provide patients with an option to standard in-office therapy. These options are especially useful for those who live in rural or underdeveloped areas, where access to mental health professionals is limited. In addition, online mental health websites offer a level of anonymity that can decrease the stigma of seeking help.

Consumer Preference for Convenience and Remote Healthcare

The preferences for convenient, remote healthcare products and services is bolstering the market growth. Today's patients increasingly want healthcare solutions that are integrated into their active lifestyle, so they can take care of themselves without having to pay repeated visits to clinics or hospitals. Digital therapeutics are addressing this need by offering tools that are available whenever and wherever needed, helping patients to control their health at their own pace. For instance, individuals suffering from chronic diseases can monitor their symptoms, monitor their vital signs, and receive treatment advice using mobile applications and wearable technology. Furthermore, digital platforms also facilitate remote consultations with medical professionals, curbing the necessity of travel and lowering healthcare expenses.

Digital Therapeutics Market Segmentation:

Breakup by Application:

  • Diabetes
  • Obesity
  • CVD
  • CNS Disease
  • Respiratory Diseases
  • Smoking Cessation
  • Others

Diabetes accounts for the majority of the market share

Diabetes holds the largest market share as it is a condition that affects millions globally. Additionally, digital therapeutics in this area leverage cutting-edge technology to monitor blood sugar levels, administer insulin doses, and provide personalized dietary and exercise recommendations. These tools aim to stabilize patient conditions and enhance the quality of life by making disease management more accessible and efficient. Hence, leading market players are introducing advanced product variants to meet these needs. For instance, on 16 October 2023, Better Therapeutics, Inc., a prominent leader in prescription digital therapeutics (PDTs) for cardiometabolic conditions, announced the commercial release of AspyreRx. This is the first cognitive behavioral therapy (CBT) app to gain U.S. Food and Drug Administration (FDA) approval as a Class II device for managing type 2 diabetes (T2D) in adults. It allows healthcare providers to prescribe AspyreRx, which is accessible for download from the Apple App Store and Google Play Store.

Breakup by End Use:

  • Patients
  • Providers
  • Payers
  • Employers
  • Others

Patients holds the largest share of the industry

According to the digital therapeutics industry overview, patients represent the largest segment due to the increasing patient-centric healthcare approach and the widespread adoption of smartphones and internet services, which facilitate easy access to therapeutic applications. These digital solutions offer patients tailored treatments for a range of conditions, including chronic diseases such as diabetes and hypertension, as well as mental health disorders. Additionally, the convenience and efficacy of these applications in managing health conditions through personalized care plans and real-time health tracking significantly contribute to their adoption among patients. This trend is further supported by growing healthcare digitization and a shift toward preventive healthcare measures, reinforcing the dominant position of patients in the digital therapeutics market. Therefore, major players are collaborating and launching sophisticated product variations. For instance, on 5 July 2023, ResMed announced the acquisition of Somnoware, a leading provider of digital diagnostics software for sleep and respiratory care. This acquisition expanded ResMed's sleep management software capabilities, facilitating more efficient patient diagnosis and long-term treatment through enhanced sleep labs and physician tools. The Somnoware platform will complement ResMed's existing post-testing solutions, AirView and Brightree, and will continue to operate as an open platform. This openness allows sleep labs, pulmonary function testing facilities, and physicians to access results from various testing solutions, accelerating the process of getting diagnosed patients the treatment they need.

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

North America leads the market, accounting for the largest digital therapeutics market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest regional market for digital therapeutics.

North America represents the leading region in the market. The digital therapeutics market growth factors for the region include the well-established healthcare infrastructure, robust technological advancements, and significant investment in digital health across the region. Moreover, the United States is primarily driven by the widespread adoption rate of digital health technologies among healthcare providers and patients alike. Besides, the presence of major digital therapeutics companies in North America, coupled with favorable government policies and a growing awareness about the benefits of digital therapeutics, further propel the market growth. For instance, on 7 November 2023, Vida Health, a leader in virtual cardiometabolic care, partnered with Withings Health Solutions, a key player in advanced everyday wearables, to provide top-tier digital monitoring devices to Vida members. This partnership offered eligible Vida members access to a Withings Body Pro cellular scale, a BPM Connect Pro cellular blood pressure monitor, or both. Vida's care teams gained reliable and consistent patient-generated health data, which enhanced their personalized care strategies and improved health outcomes by using these devices.

Competitive Landscape:

  • The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the digital therapeutics industry include 2Morrow Inc., Canary Health Inc., Click Therapeutics Inc., Mango Health Inc. (TrialCard Incorporated), Noom Health Inc., Omada Health Inc., Pear Therapeutics, Inc., Propeller Health (ResMed), Teladoc Health Inc., Voluntis Inc., and WellDoc Inc.

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

  • At present, companies are strategically enhancing their offerings and expanding their reach to bolster growth in the digital therapeutics market. Additionally, central to their efforts is forging partnerships with established healthcare entities and insurers, which helps integrate digital therapeutics into mainstream medical practice and increases patient accessibility. Moreover, various innovations by firms are advancing their technologies to improve patient engagement and outcomes through more personalized and effective treatments. Along with this, regulatory approvals are aggressively pursued to ensure compliance and enhance market credibility, crucial for broader adoption. Besides, companies invest in educational campaigns to raise awareness among healthcare professionals and patients about the benefits of digital therapeutics, aiming to shift perceptions and foster trust. These combined efforts are essential for driving the adoption and long-term viability of digital therapeutics in the healthcare landscape.

Key Questions Answered in This Report

  • 1.What was the size of the global digital therapeutics market in 2024?
  • 2.What is the expected growth rate of the global digital therapeutics market during 2025-2033?
  • 3.What are the key factors driving the global digital therapeutics market?
  • 4.What has been the impact of COVID-19 on the global digital therapeutics market?
  • 5.What is the breakup of the global digital therapeutics market based on the application?
  • 6.What is the breakup of the global digital therapeutics market based on the end use?
  • 7.What are the key regions in the global digital therapeutics market?
  • 8.Who are the key players/companies in the global digital therapeutics market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Digital Therapeutics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Application

  • 6.1 Diabetes
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Obesity
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 CVD
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 CNS Disease
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Respiratory Diseases
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Smoking Cessation
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast
  • 6.7 Others
    • 6.7.1 Market Trends
    • 6.7.2 Market Forecast

7 Market Breakup by End Use

  • 7.1 Patients
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Providers
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Payers
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Employers
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Others
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Market Breakup by Region

  • 8.1 North America
    • 8.1.1 United States
      • 8.1.1.1 Market Trends
      • 8.1.1.2 Market Forecast
    • 8.1.2 Canada
      • 8.1.2.1 Market Trends
      • 8.1.2.2 Market Forecast
  • 8.2 Asia-Pacific
    • 8.2.1 China
      • 8.2.1.1 Market Trends
      • 8.2.1.2 Market Forecast
    • 8.2.2 Japan
      • 8.2.2.1 Market Trends
      • 8.2.2.2 Market Forecast
    • 8.2.3 India
      • 8.2.3.1 Market Trends
      • 8.2.3.2 Market Forecast
    • 8.2.4 South Korea
      • 8.2.4.1 Market Trends
      • 8.2.4.2 Market Forecast
    • 8.2.5 Australia
      • 8.2.5.1 Market Trends
      • 8.2.5.2 Market Forecast
    • 8.2.6 Indonesia
      • 8.2.6.1 Market Trends
      • 8.2.6.2 Market Forecast
    • 8.2.7 Others
      • 8.2.7.1 Market Trends
      • 8.2.7.2 Market Forecast
  • 8.3 Europe
    • 8.3.1 Germany
      • 8.3.1.1 Market Trends
      • 8.3.1.2 Market Forecast
    • 8.3.2 France
      • 8.3.2.1 Market Trends
      • 8.3.2.2 Market Forecast
    • 8.3.3 United Kingdom
      • 8.3.3.1 Market Trends
      • 8.3.3.2 Market Forecast
    • 8.3.4 Italy
      • 8.3.4.1 Market Trends
      • 8.3.4.2 Market Forecast
    • 8.3.5 Spain
      • 8.3.5.1 Market Trends
      • 8.3.5.2 Market Forecast
    • 8.3.6 Russia
      • 8.3.6.1 Market Trends
      • 8.3.6.2 Market Forecast
    • 8.3.7 Others
      • 8.3.7.1 Market Trends
      • 8.3.7.2 Market Forecast
  • 8.4 Latin America
    • 8.4.1 Brazil
      • 8.4.1.1 Market Trends
      • 8.4.1.2 Market Forecast
    • 8.4.2 Mexico
      • 8.4.2.1 Market Trends
      • 8.4.2.2 Market Forecast
    • 8.4.3 Others
      • 8.4.3.1 Market Trends
      • 8.4.3.2 Market Forecast
  • 8.5 Middle East and Africa
    • 8.5.1 Market Trends
    • 8.5.2 Market Breakup by Country
    • 8.5.3 Market Forecast

9 SWOT Analysis

  • 9.1 Overview
  • 9.2 Strengths
  • 9.3 Weaknesses
  • 9.4 Opportunities
  • 9.5 Threats

10 Value Chain Analysis

11 Porters Five Forces Analysis

  • 11.1 Overview
  • 11.2 Bargaining Power of Buyers
  • 11.3 Bargaining Power of Suppliers
  • 11.4 Degree of Competition
  • 11.5 Threat of New Entrants
  • 11.6 Threat of Substitutes

12 Price Analysis

13 Competitive Landscape

  • 13.1 Market Structure
  • 13.2 Key Players
  • 13.3 Profiles of Key Players
    • 13.3.1 2Morrow Inc.
      • 13.3.1.1 Company Overview
      • 13.3.1.2 Product Portfolio
    • 13.3.2 Canary Health Inc.
      • 13.3.2.1 Company Overview
      • 13.3.2.2 Product Portfolio
    • 13.3.3 Click Therapeutics Inc.
      • 13.3.3.1 Company Overview
      • 13.3.3.2 Product Portfolio
    • 13.3.4 Mango Health Inc. (TrialCard Incorporated)
      • 13.3.4.1 Company Overview
      • 13.3.4.2 Product Portfolio
    • 13.3.5 Noom Health Inc.
      • 13.3.5.1 Company Overview
      • 13.3.5.2 Product Portfolio
    • 13.3.6 Omada Health Inc.
      • 13.3.6.1 Company Overview
      • 13.3.6.2 Product Portfolio
    • 13.3.7 Pear Therapeutics, Inc.
      • 13.3.7.1 Company Overview
      • 13.3.7.2 Product Portfolio
    • 13.3.8 Propeller Health (ResMed)
      • 13.3.8.1 Company Overview
      • 13.3.8.2 Product Portfolio
    • 13.3.9 Teladoc Health Inc.
      • 13.3.9.1 Company Overview
      • 13.3.9.2 Product Portfolio
    • 13.3.10 Voluntis Inc.
      • 13.3.10.1 Company Overview
      • 13.3.10.2 Product Portfolio
    • 13.3.11 WellDoc Inc.
      • 13.3.11.1 Company Overview
      • 13.3.11.2 Product Portfolio

List of Figures

  • Figure 1: Global: Digital Therapeutics Market: Major Drivers and Challenges
  • Figure 2: Global: Digital Therapeutics Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Digital Therapeutics Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 4: Global: Digital Therapeutics Market: Breakup by Application (in %), 2024
  • Figure 5: Global: Digital Therapeutics Market: Breakup by End Use (in %), 2024
  • Figure 6: Global: Digital Therapeutics Market: Breakup by Region (in %), 2024
  • Figure 7: Global: Digital Therapeutics (Diabetes) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 8: Global: Digital Therapeutics (Diabetes) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 9: Global: Digital Therapeutics (Obesity) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 10: Global: Digital Therapeutics (Obesity) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 11: Global: Digital Therapeutics (CVD) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 12: Global: Digital Therapeutics (CVD) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 13: Global: Digital Therapeutics (CNS Disease) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 14: Global: Digital Therapeutics (CNS Disease) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 15: Global: Digital Therapeutics (Respiratory Diseases) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 16: Global: Digital Therapeutics (Respiratory Diseases) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 17: Global: Digital Therapeutics (Smoking Cessation) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 18: Global: Digital Therapeutics (Smoking Cessation) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 19: Global: Digital Therapeutics (Other Applications) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 20: Global: Digital Therapeutics (Other Applications) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 21: Global: Digital Therapeutics (Patients) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 22: Global: Digital Therapeutics (Patients) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 23: Global: Digital Therapeutics (Providers) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 24: Global: Digital Therapeutics (Providers) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 25: Global: Digital Therapeutics (Payers) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 26: Global: Digital Therapeutics (Payers) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 27: Global: Digital Therapeutics (Employers) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 28: Global: Digital Therapeutics (Employers) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 29: Global: Digital Therapeutics (Other End Users) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 30: Global: Digital Therapeutics (Other End Users) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 31: North America: Digital Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 32: North America: Digital Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 33: United States: Digital Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 34: United States: Digital Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 35: Canada: Digital Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 36: Canada: Digital Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 37: Asia-Pacific: Digital Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 38: Asia-Pacific: Digital Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 39: China: Digital Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 40: China: Digital Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 41: Japan: Digital Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 42: Japan: Digital Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 43: India: Digital Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 44: India: Digital Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 45: South Korea: Digital Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 46: South Korea: Digital Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 47: Australia: Digital Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 48: Australia: Digital Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 49: Indonesia: Digital Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 50: Indonesia: Digital Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 51: Others: Digital Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 52: Others: Digital Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 53: Europe: Digital Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 54: Europe: Digital Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 55: Germany: Digital Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 56: Germany: Digital Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 57: France: Digital Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 58: France: Digital Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 59: United Kingdom: Digital Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 60: United Kingdom: Digital Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 61: Italy: Digital Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 62: Italy: Digital Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 63: Spain: Digital Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 64: Spain: Digital Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 65: Russia: Digital Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 66: Russia: Digital Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 67: Others: Digital Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 68: Others: Digital Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 69: Latin America: Digital Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 70: Latin America: Digital Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 71: Brazil: Digital Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 72: Brazil: Digital Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 73: Mexico: Digital Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 74: Mexico: Digital Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 75: Others: Digital Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 76: Others: Digital Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 77: Middle East and Africa: Digital Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 78: Middle East and Africa: Digital Therapeutics Market: Breakup by Country (in %), 2024
  • Figure 79: Middle East and Africa: Digital Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 80: Global: Digital Therapeutics Industry: SWOT Analysis
  • Figure 81: Global: Digital Therapeutics Industry: Value Chain Analysis
  • Figure 82: Global: Digital Therapeutics Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Digital Therapeutics Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: Digital Therapeutics Market Forecast: Breakup by Application (in Million USD), 2025-2033
  • Table 3: Global: Digital Therapeutics Market Forecast: Breakup by End Use (in Million USD), 2025-2033
  • Table 4: Global: Digital Therapeutics Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 5: Global: Digital Therapeutics Market: Competitive Structure
  • Table 6: Global: Digital Therapeutics Market: Key Players